Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease-- --Data Presented at the ...
Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy ...
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of ...
The East Stroudsburg University campus community is rallying behind a student’s effort to raise funding for muscular dystrophy that was inspired by her bond with a 9-year-old boy battling the ...
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
The Falkirk Herald on MSN3h
Fearless granny, family and friends brave the heights at the Falkirk Wheel for young FrazerA grandmother joined her son and some family friends to abseil 100 feet down from the Falkirk Wheel to raise vital cash for ...
MOVE Peds will enroll pediatric FSHD patients across eight clinical sites, capturing both early-onset and later-onset pediatric forms of the disease. Using MRI and functional testing optimized for ...
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Roche (RHHBY) announced that it will present new data at the Muscular Dystrophy Association, MDA conference, 16-19 March, 2025, in Dallas, ...
Under the deal, Peptris Technologies is licensing PEPR124 (RT001), a preclinical-stage drug, to Revio Therapeutics for ...
The competition between U.S. and Chinese biotech companies is particularly fierce in one field: CRISPR gene editing. Here are ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback